A recent study showed that diosmetin decreased APP upregulation and β-secretase (BACE1) expression, thus reducing Aβ production in advanced glycation end products (AGEs)-induced Alzheimer’s disease (AD)-like pathology in neuronal cells probably through the activation of the peroxisome proliferator-activated receptor-gamma (PPARγ) (PPARγ) pathway (Lai et al., 2022). This evidence concerns the gene BACE1 and Alzheimer disease.